gpt-4.1-2025-04-14· OpenAI LMArena Human Preference 140K
Give me a complete overview of etizolams pharmacology -- I'm a pharmacologist
- User
Give me a complete overview of etizolams pharmacology -- I'm a pharmacologist
- Assistant
Certainly! Here’s a comprehensive overview of etizolam’s pharmacology, tailored for a pharmacologist:
1. Chemical Structure and Classification
- Chemical Name: 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
- Molecular Formula: C17H15ClN4S
- Class: Thienotriazolodiazepine (not a classical benzodiazepine, but closely related)
- Structural Note: The benzene ring of the classic benzodiazepine is replaced by a thiophene ring, and a triazole ring is fused to the diazepine core.
2. Mechanism of Action
- Primary Target: Positive allosteric modulator of the GABA(_A) receptor.
- Binding Site: Binds at the benzodiazepine site on the GABA(_A) receptor complex.
- Effect: Enhances the affinity of GABA for its receptor, increasing the frequency of chloride channel opening, leading to hyperpolarization and neuronal inhibition.
- Subtype Selectivity: Prefers α1, α2, α3, and α5 subunits of GABA(_A) receptors, similar to classical benzodiazepines.
3. Pharmacodynamics
- CNS Effects: Anxiolytic, hypnotic, sedative, anticonvulsant, muscle relaxant, and amnesic properties.
- Potency: Approximately 6–10 times more potent than diazepam (varies by endpoint).
- Onset/Duration: Rapid onset, short to intermediate duration of action.
- Tolerance/Dependence: Similar risk profile to benzodiazepines, but some reports suggest a faster development of tolerance and dependence.
4. Pharmacokinetics
Absorption
- Bioavailability: ~93% (oral)
- Onset: 30–60 minutes (oral)
- Peak Plasma: 0.5–2 hours
Distribution
- Volume of Distribution: ~0.7 L/kg
- Plasma Protein Binding: ~93%
Metabolism
- Primary Pathway: Hepatic, mainly via CYP3A4.
- Major Metabolites:
- α-hydroxyetizolam (active, ~10–20% potency of parent)
- 8-hydroxyetizolam (inactive)
- Conjugation: Glucuronidation of metabolites.
Elimination
- Half-life: 3–6 hours (parent), 8 hours (α-hydroxyetizolam)
- Excretion: Renal (as metabolites and conjugates)
5. Clinical Use and Indications
- Approved in: Japan, Italy, India (not FDA-approved in the US or most of Europe)
- Indications: Short-term treatment of anxiety, panic disorder, insomnia.
- Off-label/Illicit Use: Increasingly found as a designer drug or in counterfeit benzodiazepine tablets.
6. Adverse Effects
- Common: Drowsiness, sedation, muscle relaxation, ataxia, cognitive impairment.
- Serious: Respiratory depression (especially with other CNS depressants), paradoxical reactions (agitation, aggression), dependence, withdrawal syndrome.
- Unique: Some reports suggest a lower risk of amnesia and less pronounced muscle relaxant effects compared to classical benzodiazepines.
7. Drug Interactions
- CYP3A4 Inhibitors: (e.g., ketoconazole, erythromycin) increase etizolam levels.
- CYP3A4 Inducers: (e.g., carbamazepine, rifampin) decrease etizolam levels.
- Other CNS Depressants: Additive/synergistic effects (alcohol, opioids, other sedatives).
8. Toxicology and Overdose
- Symptoms: Profound sedation, respiratory depression, hypotonia, ataxia, coma (rarely fatal unless combined with other depressants).
- Antidote: Flumazenil (benzodiazepine site antagonist), but use with caution due to risk of seizures.
9. Legal Status
- Controlled in: Many countries (Schedule IV in Italy, Schedule 8 in Australia, Class C in the UK, etc.)
- Not scheduled: In some countries, but often subject to analog laws or specific bans.
10. Distinguishing Features from Classical Benzodiazepines
- Structure: Thienotriazolodiazepine, not a true benzodiazepine.
- Potency: Higher potency, shorter half-life.
- Metabolism: Active metabolite (α-hydroxyetizolam) extends effects.
- Clinical Profile: Somewhat less muscle relaxant and amnestic effect, but more rapid tolerance.
References
- PubChem: Etizolam
- EMCDDA: Etizolam Drug Profile
- Ishikawa et al., 2015, Forensic Toxicol 33: 12–23
- Mancuso et al., 2019, CNS Drugs 33: 219–232
If you need more detail on any specific aspect (e.g., receptor subtype pharmacology, comparative studies, or analytical detection), let me know!
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.